B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL [Phase 2]
A Phase II trial is evaluating a four-drug combination (mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide) in relapsed B-cel…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial by ImmunityBio for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) [Phase 1]
This clinical trial update describes an ongoing Phase 1 study evaluating loncastuximab tesirine in combination with other anticancer agents …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL [Phase 1]
This clinical trial update describes a Phase 1 study of GB5005 CART-cell injection targeting CD19 in patients with relapsed or refractory B-…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating CD19/CD22 bicistronic CAR T cells in children and young adults with recurrent or refractory CD19/CD…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CD45BE-HSPC + CART-45 Cells [Phase 1]
Phase 1 study evaluating CD45BE-HSPC with CART-45 cells is not yet recruiting and targets B-cell non-Hodgkin lymphoma and Richter transforma…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) [Phase 1]
Phase 1 trial update for a CD19-targeted CAR T cell therapy in pediatric patients with relapsed or refractory B cell acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study of TORL-5-700 is evaluating its safety and early efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma; the trial…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]
A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial from City of Hope evaluating CMV-specific CD19-CAR T-cells with CMV-MVA Triplex vaccine after stem cell transplantati…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma [Phase 2, Phase 3]
Global pediatric/adolescent trial evaluating novel agents for relapsed and refractory B-cell non-Hodgkin lymphoma. The study is currently re…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory o…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL [Phase 1]
Phase 1 study evaluating CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; th…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 [Phase 1]
Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012 in relapsed or refractory B-…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL [Phase 1]
A Phase 1 clinical trial evaluating the XP-006 mRNA vaccine for relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruit…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study evaluating fully human bispecific CAR T cells targeting CD20 and CD19 in relapsed or re…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors [Phase 2]
A Phase 2 clinical trial evaluating CAR-T therapy after autologous stem cell transplant for relapsed/refractory B-cell non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This document provides an update on a Phase 1 clinical study of RN1701 Injection for relapsed/refractory B-cell non-Hodgkin lymphoma. The st…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
A prospective observational cohort study assessing the clinical impact of novel monoclonal antibodies in B-cell non-Hodgkin lymphoma within …
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial is evaluating the safety and activity of SAR448501/DR-0201 in patients with relapsed or refractory B-cell non-Hodgkin lym…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]
Phase I clinical trial update for JS203 in relapsed/refractory B-cell non-Hodgkin's lymphoma, with the study listed as active but not recrui…